Atamyo Therapeutics
Clinical trials sponsored by Atamyo Therapeutics, explained in plain language.
-
Gene therapy hope for kids with rare Muscle-Wasting disease
Disease control OngoingThis early-stage study tests a single intravenous gene therapy (ATA-200) in 4 children aged 6-12 with limb girdle muscular dystrophy type 2c (LGMD2C), a rare genetic muscle disease. The main goal is to check safety and side effects, not to cure the disease. Participants must be a…
Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Experimental gene therapy hopes to stop rare muscle disease
Disease control OngoingThis early-stage trial tests a new gene therapy (GNT0006) for people with a rare genetic muscle disease called LGMDR9. The study involves 6 participants who receive a single intravenous dose to deliver a working copy of the FKRP gene. The main goal is to check the treatment's saf…
Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
Researchers to watch rare muscle disease progression without treatment
Knowledge-focused TerminatedThis study aims to learn more about how gamma-sarcoglycanopathy (LGMDR5) changes over time. It will follow people aged 6 to 35 with a confirmed diagnosis for up to 24 months, measuring muscle function, breathing, and daily activity. No new treatments are tested; the goal is to ga…
Sponsor: Atamyo Therapeutics • Aim: Knowledge-focused
Last updated May 22, 2026 14:02 UTC